长期抗生素抑制在DAIR治疗假体周围关节感染中的作用:系统综述
该系统综述纳入7项低质量(III或IV级)研究、437例假体周围关节感染(PJI)病例,评估DAIR术后联合长期(>1年)抑制性抗生素治疗(SAT)的效果。结果显示DAIR后SAT的平均无感染率为75%(318/424),全因再手术率为6.7%,长期抗生素不良反应平均发生率为15.4%,导致停药的不良反应率为4.3%。现有证据质量低,不足以得出明确结论。
要点
- DAIR联合SAT的平均无感染率为75%,全因再手术率为6.7%。
- 长期抗生素不良反应发生率为15.4%,因不良反应停药率为4.3%。
- 现有证据质量低(III-IV级),需高质量前瞻性研究验证SAT疗效与安全性。
核心结论
- DAIR联合SAT的证据质量仍低,不足以得出明确结论,需高质量前瞻性研究。
- 尽管因副作用停药率低,但不良反应发生率高,反映PJI患者脆弱复杂且治疗不理想。
- 金黄色葡萄球菌似乎是SAT失败的风险因素,但数据不足以确定哪些患者最受益。
研究设计与样本
- 纳入7项低质量(III或IV级)研究,共437例PJI病例,均行DAIR后接受SAT。
主要发现
- DAIR后SAT的平均无感染率为75%(318/424例患者)。
- 全因再手术率为6.7%。
- 长期抗生素不良反应平均发生率为15.4%,导致停药的不良反应率为4.3%。
- 无研究显示急性感染(症状出现≤4周)与慢性感染(症状出现>4周)的DAIR联合SAT失败率有显著差异。
- 关于解剖部位(髋 vs 膝)和微生物对DAIR联合SAT成功率的影响,文献结论不一致。
关键数值与推荐
- 长期抑制性抗生素治疗(SAT)定义为>1年。
- 急性感染定义为症状出现≤4周(术后或血源性),慢性感染定义为症状出现>4周。
临床怎么用
- DAIR联合SAT可作为PJI的治疗选择,但需权衡15.4%的不良反应风险。
- 金黄色葡萄球菌感染可能增加SAT失败风险,临床决策时需考虑。
- 因证据质量低,应个体化评估患者获益与风险,并优先考虑高质量研究证据。
局限性
- 纳入研究均为低质量(III或IV级),证据等级有限。
- 缺乏高质量前瞻性对照研究,无法得出确定性结论。
- 解剖部位和微生物对疗效的影响尚无一致结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A number of clinical trials have been conducted, assessing the role of long-term (>1 year) suppressive antibiotic treatment (SAT) combined with Debridement, Antibiotics, and Implant Retention (DAIR) for the management of peri-prosthetic joint infection (PJI). However, no systematic review of the literature has been published to date to evaluate complications associated with long-term antibiotic treatment and overall survivorship free from re-operation and revision for infection after DAIR for total hip and total knee PJI. METHODS: The US National Library of Medicine (PubMed/MEDLINE), EMBASE, and the Cochrane Database of Systematic Reviews were queried for publications from January 1980 to December 2018 utilizing keywords pertinent to total knee arthroplasty, total hip arthroplasty, PJI, and antibiotic suppression. RESULTS: Overall, 7 articles of low quality (level III or IV) were included in this analysis. The studies included in this systematic review included 437 cases of PJI treated surgically with DAIR and then with SAT. The overall mean infection-free rate of SAT following DAIR was 75% (318/424 patients), while the all-cause re-operation rate was 6.7%. Overall, the mean rate of adverse effects associated with long-term antibiotic use was 15.4% and the mean rate of adverse effects leading to discontinuation of SAT was 4.3%. There was no study to show significant differences between acute (either post-operative or hematogenous, with onset of symptoms ≤4 weeks) and chronic (onset of symptoms >4 weeks) infections and failure rates of DAIR with SAT. The literature is inconclusive on the influence of anatomic location (hip vs knee) as well as microorganism on the success rate of DAIR with SAT. CONCLUSION: The results of this systematic review demonstrate that there is still only low-quality evidence regarding the therapeutic effect of DAIR combined with SAT, which is not enough to draw definitive conclusions. Furthermore, high-quality prospective studies are needed to better understand SAT's efficacy and safety in a controlled fashion. Although discontinuation of antibiotic treatment due to side effects was found to be low, the high rates of adverse effects noted after DAIR with SAT demonstrate the underlying frailty and complexity of many patients with PJI, and the imperfect therapies available. Although Staphylococcus aureus appears to be a risk factor for increased risk of SAT failure, there are not enough data to establish which patients would benefit most from DAIR with post-operative SAT.
引用
- Malahias MA, Gu A, Harris EC, et al. The Role of Long-Term Antibiotic Suppression in the Management of Peri-Prosthetic Joint Infections Treated With Debridement, Antibiotics, and Implant Retention: A Systematic Review. J Arthroplasty. 2019. PMID: 31955984. doi:10.1016/j.arth.2019.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。